131 related articles for article (PubMed ID: 12672578)
1. Gemifloxacin: effects of sub-inhibitory concentrations on various factors affecting bacterial virulence.
Dal Sasso M; Culici M; Bovio C; Braga PC
Int J Antimicrob Agents; 2003 Apr; 21(4):325-33. PubMed ID: 12672578
[TBL] [Abstract][Full Text] [Related]
2. Interference of sub-inhibitory concentrations of gatifloxacin on various determinants of bacterial virulence.
Dal Sasso M; Bovio C; Culici M; Braga PC
J Chemother; 2002 Oct; 14(5):473-82. PubMed ID: 12462427
[TBL] [Abstract][Full Text] [Related]
3. Sub-MIC concentrations of cefodizime interfere with various factors affecting bacterial virulence.
Braga PC; Sasso MD; Sala MT
J Antimicrob Chemother; 2000 Jan; 45(1):15-25. PubMed ID: 10629008
[TBL] [Abstract][Full Text] [Related]
4. Staphylococcus aureus and Escherichia coli adhesion to human cells is reduced by sub-MICs of gemifloxacin.
Braga PC; Dal SM; Woodnutt G
J Chemother; 2002 Feb; 14(1):41-6. PubMed ID: 11892898
[TBL] [Abstract][Full Text] [Related]
5. Pharmacodynamic effects of subinhibitory concentrations of rufloxacin on bacterial virulence factors.
Braga PC; Sala MT; Dal Sasso M
Antimicrob Agents Chemother; 1999 May; 43(5):1013-9. PubMed ID: 10223908
[TBL] [Abstract][Full Text] [Related]
6. Comparative anti-staphylococcal effects of gemifloxacin and trovafloxacin in an in vitro dynamic model in terms of AUC/MIC and dose relationships.
Zinner SH; Vostrov SN; Lubenko IY; Portnoy YA; Cornaglia G; Firsov AA
Diagn Microbiol Infect Dis; 2001 Aug; 40(4):167-71. PubMed ID: 11576789
[TBL] [Abstract][Full Text] [Related]
7. Gemifloxacin and ciprofloxacin pharmacodynamics in an in-vitro dynamic model: prediction of the equivalent AUC/MIC breakpoints and doses.
Firsov AA; Zinner SH; Lubenko IYu ; Vostrov SN
Int J Antimicrob Agents; 2000 Dec; 16(4):407-14. PubMed ID: 11118849
[TBL] [Abstract][Full Text] [Related]
8. Cellular accumulation of fluoroquinolones is not predictive of their intracellular activity: studies with gemifloxacin, moxifloxacin and ciprofloxacin in a pharmacokinetic/pharmacodynamic model of uninfected and infected macrophages.
Vallet CM; Marquez B; Ngabirano E; Lemaire S; Mingeot-Leclercq MP; Tulkens PM; Van Bambeke F
Int J Antimicrob Agents; 2011 Sep; 38(3):249-56. PubMed ID: 21764262
[TBL] [Abstract][Full Text] [Related]
9. Effects of sub-minimum inhibitory concentrations of gatifloxacin on the inhibition of Staphylococcus aureus and Escherichia coli adherence.
Braga PC; Dal Sasso M
Arzneimittelforschung; 2002; 52(2):109-12. PubMed ID: 11878198
[TBL] [Abstract][Full Text] [Related]
10. Interference by subinhibitory concentrations of azithromycin with the mechanism of bacterial adhesion to human epithelial cells.
Braga PC; Piatti G
Chemotherapy; 1993; 39(6):432-7. PubMed ID: 8222872
[TBL] [Abstract][Full Text] [Related]
11. In vitro activity of gemifloxacin and five other fluoroquinolones against defined isogenic mutants of Escherichia coli, Pseudomonas aeruginosa and Staphylococcus aureus.
Schulte A; Heisig P
J Antimicrob Chemother; 2000 Dec; 46(6):1037-8. PubMed ID: 11102429
[No Abstract] [Full Text] [Related]
12. Ex vivo efficacy of gemifloxacin in experimental keratitis induced by methicillin-resistant Staphylococcus aureus.
Marino A; Blanco AR; Ginestra G; Nostro A; Bisignano G
Int J Antimicrob Agents; 2016 Oct; 48(4):395-400. PubMed ID: 27554440
[TBL] [Abstract][Full Text] [Related]
13. Effect of low concentrations of quinolone antibiotics on bacterial virulence mechanisms.
Sonstein SA; Burnham JC
Diagn Microbiol Infect Dis; 1993; 16(4):277-89. PubMed ID: 8388327
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of bacterial adhesion by sub-inhibitory concentrations: brodimoprim vs trimethoprim.
Braga PC; Piatti G; Limoli A; Santoro M; Gazzola T
J Chemother; 1993 Dec; 5(6):447-52. PubMed ID: 8195836
[TBL] [Abstract][Full Text] [Related]
15. Antimicrobial activity and a comparison of published pharmacodynamics of gemifloxacin and eight fluoroquinolones against Streptococcus pneumoniae.
Saravolatz L; Manzor O; Pawlak J; Belian B
Int J Antimicrob Agents; 2005 Jul; 26(1):81-4. PubMed ID: 15951159
[TBL] [Abstract][Full Text] [Related]
16. Pharmacodynamics of gemifloxacin against Streptococcus pneumoniae in an in vitro pharmacokinetic model of infection.
MacGowan AP; Rogers CA; Holt HA; Wootton M; Bowker KE
Antimicrob Agents Chemother; 2001 Oct; 45(10):2916-21. PubMed ID: 11557490
[TBL] [Abstract][Full Text] [Related]
17. Favourable effects of sub-MIC rufloxacin concentrations in decreasing the pathogen-host cell adhesion.
Braga PC; Piatti G
Pharmacol Res; 1993; 28(1):11-9. PubMed ID: 8234142
[TBL] [Abstract][Full Text] [Related]
18. Relationships of the area under the curve/MIC ratio to different integral endpoints of the antimicrobial effect: gemifloxacin pharmacodynamics in an in vitro dynamic model.
Firsov AA; Lubenko IY; Portnoy YA; Zinner SH; Vostrov SN
Antimicrob Agents Chemother; 2001 Mar; 45(3):927-31. PubMed ID: 11181382
[TBL] [Abstract][Full Text] [Related]
19. Efficacy of gemifloxacin for the treatment of experimental Staphylococcus aureus keratitis.
Wu X; Jiang H; Xu Y; Yue W; Yang L; Song Z; Chen H; Liu T
J Ocul Pharmacol Ther; 2012 Aug; 28(4):420-7. PubMed ID: 22360669
[TBL] [Abstract][Full Text] [Related]
20. Gemifloxacin: a new fluoroquinolone approved for treatment of respiratory infections.
Yoo BK; Triller DM; Yong CS; Lodise TP
Ann Pharmacother; 2004; 38(7-8):1226-35. PubMed ID: 15187209
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
